Kiora Pharmaceuticals (KPRX) Competitors $2.72 -0.10 (-3.55%) Closing price 03:58 PM EasternExtended Trading$2.82 +0.10 (+3.82%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. XFOR, PLUR, MRSN, OKUR, JSPR, SNTI, MURA, RANI, TENX, and EGRXShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include X4 Pharmaceuticals (XFOR), Pluri (PLUR), Mersana Therapeutics (MRSN), OnKure Therapeutics (OKUR), Jasper Therapeutics (JSPR), Senti Biosciences (SNTI), Mural Oncology (MURA), Rani Therapeutics (RANI), Tenax Therapeutics (TENX), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors X4 Pharmaceuticals Pluri Mersana Therapeutics OnKure Therapeutics Jasper Therapeutics Senti Biosciences Mural Oncology Rani Therapeutics Tenax Therapeutics Eagle Pharmaceuticals Kiora Pharmaceuticals (NASDAQ:KPRX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Does the media prefer KPRX or XFOR? In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 2 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 0.95 equaled X4 Pharmaceuticals'average media sentiment score. Company Overall Sentiment Kiora Pharmaceuticals Positive X4 Pharmaceuticals Positive Is KPRX or XFOR more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -311.15%. Kiora Pharmaceuticals' return on equity of -47.17% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -47.17% -34.00% X4 Pharmaceuticals -311.15%-375.31%-72.87% Do institutionals & insiders believe in KPRX or XFOR? 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, KPRX or XFOR? Kiora Pharmaceuticals has a beta of -0.67, indicating that its share price is 167% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Do analysts recommend KPRX or XFOR? Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 267.65%. X4 Pharmaceuticals has a consensus price target of $34.17, indicating a potential upside of 1,005.72%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00X4 Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation & earnings, KPRX or XFOR? Kiora Pharmaceuticals has higher earnings, but lower revenue than X4 Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.58$3.60M-$2.91-0.93X4 Pharmaceuticals$32.77M1.08-$37.45M-$14.84-0.21 SummaryX4 Pharmaceuticals beats Kiora Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.33M$2.59B$6.01B$10.23BDividend YieldN/A56.68%5.66%4.69%P/E Ratio-0.9322.9285.3526.57Price / Sales0.58612.59582.95179.01Price / Cash2.20177.3038.3262.20Price / Book0.325.3712.726.53Net Income$3.60M$32.78M$3.30B$275.87M7 Day Performance-1.09%2.40%1.07%-1.40%1 Month Performance0.37%10.27%7.61%5.16%1 Year Performance-16.56%-0.18%79.71%31.51% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.2938 of 5 stars$2.72-3.5%$10.00+267.6%-16.1%$9.33M$16.02M-0.9310Positive NewsAnalyst ForecastXFORX4 Pharmaceuticals4.2272 of 5 stars$3.34-0.4%$34.17+924.5%-78.5%$38.22M$2.56M-0.2380Analyst ForecastGap DownPLURPluri2.1449 of 5 stars$4.66+1.1%$12.00+157.5%-12.1%$38.01M$1.34M-0.90150Analyst ForecastMRSNMersana Therapeutics4.3572 of 5 stars$7.57-2.9%$56.60+648.2%-80.7%$37.75M$40.50M-0.52150News CoverageAnalyst ForecastOKUROnKure Therapeutics3.7013 of 5 stars$2.78+3.9%$32.33+1,065.2%N/A$37.55MN/A-0.58N/AAnalyst ForecastJSPRJasper Therapeutics3.403 of 5 stars$2.32-7.0%$25.63+1,006.9%-83.5%$37.38MN/A-0.3820Analyst ForecastSNTISenti Biosciences2.4127 of 5 stars$1.41+0.4%$8.50+505.0%-12.8%$37.02MN/A-0.164Analyst ForecastMURAMural Oncology3.2876 of 5 stars$2.09+0.2%$12.00+475.5%-38.3%$36.13MN/A-0.24119Analyst ForecastRANIRani Therapeutics3.3161 of 5 stars$0.50+1.4%$7.33+1,375.5%-79.5%$35.79M$1.20M-0.55110Analyst ForecastTENXTenax Therapeutics1.8812 of 5 stars$7.72+5.9%$18.00+133.2%+129.9%$35.23MN/A-8.399High Trading VolumeEGRXEagle Pharmaceuticals1.3657 of 5 stars$2.70-4.4%N/A+72.0%$35.07M$257.55M0.00100Gap Down Related Companies and Tools Related Companies X4 Pharmaceuticals Competitors Pluri Competitors Mersana Therapeutics Competitors OnKure Therapeutics Competitors Jasper Therapeutics Competitors Senti Biosciences Competitors Mural Oncology Competitors Rani Therapeutics Competitors Tenax Therapeutics Competitors Eagle Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredThe best AI stock you aren’t watching (but Elon is)Elon Musk's AI empire is already being built... not in the spotlight, but in the background. One public cou...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
